Cerebras Systems raised $5.55 billion in the largest US technology IPO since Uber's 2019 debut, opening at $350 against a $185 offer price before pulling back 10% on its second trading day
Cerebras Systems (ticker: CBRS) is an AI chip company whose core product, the Wafer Scale Engine 3, is built by treating an entire silicon wafer as a single processor rather than cutting it into individual chips – an approach the company says runs AI inference, the process of generating outputs from an already-trained model, up to 15 times faster than competing products. The company priced 30 million Class A shares at $185 on May 13, 2026, and began trading on the Nasdaq Global Select Market on May 14. The stock opened at $350 – nearly double the offer price – reached an intraday high of $385, and closed at $311.07, a 68% first-day gain. The offering raised $5.55 billion. On May 15, shares fell a further 10.08%, closing at $279.72.
Cerebras had originally marketed shares at $150–$160, raising both the size and the price range in response to demand that exceeded available shares by more than 20 times. Revenue at the company grew 76% in 2025 to $510 million, and the company generated net income of $88 million, compared with a net loss of $481.6 million the prior year. One material risk disclosed in regulatory filings: more than 85% of Cerebras' 2024 revenue came from G42, a UAE-based AI company, a concentration that previously drew US regulatory scrutiny before being cleared. Cerebras has also established partnerships with Amazon and OpenAI, with OpenAI launching its first AI model running on Cerebras chips earlier in 2026. The valuation at Day 1 close was ~$70 billion based on outstanding shares per regulatory filings, or ~$86 billion on a fully diluted basis per Bloomberg data; Reuters placed the fully diluted figure at $56.43 billion at the IPO price – a range reflecting genuinely different methodologies for counting diluted shares.
The valuation range conflict between Bloomberg (~$86B fully diluted) and Reuters ($56.43B at IPO price) is not a rounding error – it reflects genuinely different assumptions about option and warrant dilution. Portfolio managers should obtain and model the full diluted share count from the S-1 before setting position size limits; the Day 2 drop suggests the market is still discovering the correct denominator. Do this before the next trading session, not after a further decline forces the decision.
The customer concentration risk – 85%+ of 2024 revenue from G42 – is a meaningful vendor viability signal. CTOs considering Cerebras chips for 2027 infrastructure plans should request written confirmation of supply volume commitments and customer diversification milestones before committing to integration work. Ask for those milestones in writing at your next vendor meeting.
The 20× oversubscription and 68% Day 1 gain sets a public market reference point for inference-chip valuations. Begin preparing S-1-ready financials now, and expect investor diligence to focus heavily on customer concentration ratios and gross margin trajectory – those were the two issues most prominently raised in analyst commentary on Cerebras. A clean story on both is a prerequisite for a successful filing.